With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

DelveInsight's "TIBSOVO Market Size, Forecast, and Market Insight Report" highlights the details around TIBSOVO, the first ...

Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. | Servier’s decision to exit a Parkinson’s disease pact has ...

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision ...

Plus, news about Cen­tu­ry Ther­a­peu­tics, Ake­bia Ther­a­peu­tics, Eye­n­ovia, Be­taliq, Alvotech, Genen­ta Sci­ence, Aa­di Bio­science, and Ex­i­cure: ...

Further research revealed that one of these drugs, DDL-920 – developed at UCLA, led to the complete recovery of movement control – something many stroke patients never regain.

The therapy is undergoing Phase I clinical development. Credit: Alex_Traksel/Shutterstock. Servier and Black Diamond Therapeutics have signed a licensing agreement ...

Some countries will also use IRP to help determine the eligibility of certain products for reimbursement. There is a growing awareness, however, of the repercussions of IRP, including drug shortages, ...

"Servier's commitment to innovation and deep ... the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe, and ...

Black Di­a­mond Ther­a­peu­tics has found a buy­er for an ear­ly-stage tar­get­ed can­cer drug, which was brushed to the side last year as it fo­cused re­sources … ...

Servier will lead the development activities ... Also Read: Black Diamond Therapeutics’ Lead Drug Candidate Shows Initial Anti-Tumor Activity In Certain Type Of Lung Cancer Resistant To ...

the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond concluded its attempt to push two cancer drugs through ...